期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 39, 期 -, 页码 71-78出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2016.07.013
关键词
Adjuvant; Cancer immunotherapy; C3H/HeJ; siRNA
资金
- Korean government [NRF-2008-0062275, MOTIE-1415139249]
- Korean government (Functional Districts of the Science Belt Support program)
Curdlan, a beta-1,3-glucan isolated from Alcaligenes faecalis, is an agonist of dectin-1 in various immune cells, including dendritic cells (DCs). However, whether curdlan also activates DCs through other receptors remains unknown. In this study, we found that curdlan activates DCs through dectin-1 and toll-like receptor 4 (TLR4). Curdlan increased the expression levels of surface molecules (CD40, CD80, CD86, and MHC-I/II), the production of cytokines (IL-12, IL-1 beta, TNF-alpha, and IFN-beta), migration toward MIP-3 beta, and allogeneic T cell stimulation activity of DCs. Curdlan increased the phosphorylation of Syk, Raf-1, Akt, MAPKs, IKK, and NF-kappa B p65 in DCs. However, curdlan only slightly activated DCs transfected with small interfering RNAs against dectin-1 or TLR4 and C3H/HeJ DCs, which have non-functional TLR4, in comparison with control DCs. Curdlan increased antitumor activity of DCs in a syngeneic tumor model. In summary, our data show that curdlan activates DCs through dectin-1 and TLR4 signaling and the combination of curdlan and DCs efficiently inhibit tumor growth in mice. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据